August 5, 2016 by Ćzge Ćzkaya, PhD Gut Microbiota Is Growing Focus of Multiple Sclerosis Research, Though Treatments Are Few Gut microbiota (the ecological community of microorganisms that live in the gut) may be an important environmental risk factor for multiple sclerosis (MS). This suggests that strategies to correct the imbalance in the normal intestinal flora, also known as microbial dysbiosis may help treat or event prevent MS.
June 10, 2016 by admin Aggressive Stem Cell Therapy Stops MS Relapses, According to Long-term Clinical Trial Stem cell treatment has been proven to both halt MS clinical relapses and the development of new brain lesions over a prolonged period, according to the results of a new study. The results, achieved in 23 out of 24 patients in a Phase 2 clinical trial, were published in…
May 26, 2016 News by BioNews Staff MS Australia Puts Out an Owner’s Manual for ‘MS Bike’ and Anyone Willing to Take It for a Spin A bicycle specially designed to mimic the symptoms of multiple sclerosis (MS) now has its own owner’s manual, and the group behind the bike’s creation is inviting anyone interested to build their own experience of the spasticity and physical discomforts so well-known to people with the disease. The manual, which…
February 18, 2016 News by BioNews Staff FDA Grants ‘Breakthrough Therapy’ Designation to Genentechās Ocrelizumab for PPMS Genentech recently announced that the U.S. Food and Drug Administration (FDA) granted its investigational medicine ocrelizumab, a potential treatment forĀ primary progressive multiple sclerosis (PPMS),Ā Breakthrough Therapy DesignationĀ based on positiveĀ Phase 3 clinical trial results showing thatĀ ocrelizumab significantly reduced disability progression and other disease activity markers compared toĀ placebo. The FDA designation is…
January 5, 2016 News by Patricia Silva, PhD Review Highlights Long List of Unmet Needs For MS Patients In a special feature publishedĀ in the journal American Health & Drug Benefits, authorsĀ Stanton R. Mehr, President of SM Health Communications, and Marj P. Zimmerman, President of RxDirections, discuss the many unmet medical needs multiple sclerosis (MS) patients still face in dealing with the…
December 3, 2015 by BioNews Staff Coral Gables, FL MS Exchange Event This Saturday To Explore Relapsing MS Management An interactive event in Coral Gables, FL this weekend will give relapsing Multiple Sclerosis patients who live in the area access to best practices and therapeutic insights that can help them better manage the disease.Ā The Coral Gables MS Exchange eventĀ will be held from 10:30 a.m. to 2:15 p.m. on…
November 19, 2015 News by Patricia Silva, PhD Might Chocolate Ease Multiple Sclerosis Fatigue? A research team from Oxford Brookes UniversityĀ is being given aĀ Ā£70,000 ($107,000) grant to analyze whether dark chocolate can help ease symptoms of multiple sclerosis (MS). The Multiple Sclerosis Society (MS Society) will fund the study. The goal of the project, according to aĀ press release,Ā is to investigate if a…
November 13, 2015 News by Patricia Inacio, PhD Could Remyelination Be Achieved in MS Using an Anti-Inflammatory Treatment? In a recent study entitled āPromotion of Remyelination by Sulfasalazine in a Transgenic Zebrafish Model of Demyelination,ā researchers investigated whetherĀ sulfasalazine treatment, an anti-inflammatory and immune-modulating drug, could promote remyelination of axons in an organism model of demyelination diseases such as multiple sclerosis (MS). The study was published in the…
November 10, 2015 News by Charles Moore Free MS Exchange Interactive Events Coming to San Antonio and Coral Gables (Miami) Two upcoming, free events for members of the multiple sclerosis community are to be held during the next few weeks at Coral Gables, Florida, and San Antonio, Texas, respectively. Sponsored by the pharmaceutical firm Genzyme, these interactive events will provide opportunities for peopleĀ with MS and members of the MS community…
November 3, 2015 News by Patricia Silva, PhD Psychiatric Comorbidity Among Multiple Sclerosis Patients Reported to Be Common Psychiatric comorbidity is common in patients with multiple sclerosis (MS), and affects the MS community more frequentlyĀ than a matched control population, although the incidence is stable over time, according to recent findings of a study published in the journal Neurology, the Official Journal of the American Academy…
October 23, 2015 News by Charles Moore Cannabis-Derived Sativex for MS-Related Spasticity Reported to Be Effective and Safe Barcelona, Spain-based, global pharma firm Almirall presented new clinical evidence at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) ā held in Barcelona October 7ā10, 2015 ā supporting the efficacy of its Sativex product, currently the only pharmaceutical medicine derived from cannabinoids…
October 20, 2015 News by Patricia Inacio, PhD Generic Form of Glatiramer Acetate Has Equivalent Gene Expression Profile as Teva’s Copaxone In a recent study entitled āEquivalent Gene Expression Profiles between Glatopaā¢ and CopaxoneĀ®,ā authors determined potential differences in treatment responses by investigating the gene expression profile of two approved treatments for relapsing forms of multiple sclerosis ā Copaxone and Glatopa. Both of these MS therapies are glatiramer…
October 15, 2015 News by Maureen Newman The Future of Stem Cell Therapy for Multiple Sclerosis Patients Relies on Clinical Trial Participation Among the different therapeuticĀ approaches being explored for treating MS,Ā adult stem cell therapy continues to beĀ one of the most discussed and anticipatedĀ in the MS community. āStem cellsā ā the common term for undifferentiated, self-renewing proliferating cells āĀ are currently being investigated for their ability to treatĀ patients in a wide range of disease…
October 13, 2015 News by Patricia Silva, PhD Importance of Microbiota in MS Development Explored in ECTRIMS 2015 Presentation Three parallel sessions concerning multiple sclerosis (MS) prevention, clinical phenotypes and magnetic resonance imaging (MRI) were featured at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), recently held in Barcelona, Spain (October 7 ā 10, 2015). The first parallel session was entitled āWill…
October 12, 2015 News by Patricia Silva, PhD Update on Alemtuzumab (Genzyme’s Lemtrada) Clinical Trial Data Presented at ECTRIMS 2015 Multiple Sclerosis News Today recently attended the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)Ā held in Barcelona, Spain, October 7 to 10, 2015. On Friday, October 9, three parallel sessions entitled āFree Communicationsā took place. In the first session, several topics related to multiple…
October 9, 2015 News by Patricia Silva, PhD New 3-Times-Per-Week Regimen For Teva’s Copaxone Safe, Effective & Increases Patient Compliance #ECTRIMS2015 A Satellite Symposia entitled āDiscovering a new world in MSā presentedĀ by Teva Neuroscience was held yesterday, October 8 at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)Ā currently taking place in Barcelona, Spain, October 7 ā 10, 2015. Dr. Omar Khan from the…
October 9, 2015 News by Patricia Silva, PhD Potential MS Drug Cladribine Reported To Have No Impact on Cancer Incidence A new study recently published in the journal Neurology: Neuroimmunology & Neuroinflammation revealed that the drug Cladribine does not increase the risk of cancer in patients with multiple sclerosis (MS) as previously thought. The study was led by researchers at Queen Mary University of London (QMUL)…
October 9, 2015 News by Patricia Inacio, PhD Ocrelizumab: Could Genentech/Rocheās Experimental Drug Be the First Effective Progressive MS Therapy? Roche announced positive results for three pivotal Phase III studies of experimental MS therapy ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis (PPMS) patients at this year’s ECTRIMS 2015 conference. The results, particularly for treating PPMS, indicate that the novel therapy may represent…
October 8, 2015 News by admin Does Sun Exposure in Early Years Delay MS Onset? Exposure to sunlight may delay the development of multiple sclerosis (MS), according to a new study from researchers in Denmark. The work, titled “Association between age at onset of multiple sclerosis and vitamin D levelārelated factors,” appeared October 7, 2015 in the journal Neurology.
October 8, 2015 News by Patricia Silva, PhD MS Care: A Hot Topic at #ECTRIMS2015 Three āHot Topic Sessionsā on multiple sclerosis will take place this afternoon (17:00 ā 17:45 h, GMT + 1h) at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), currently being held in Barcelona, Spain, October 7 ā 10. The first session is entitled…
October 8, 2015 News by Patricia Silva, PhD Acorda To Present New Data on MS Therapies AMPYRA and Experimental rHIgM22 at #ECTRIMS2015 Acorda Therapeutics, Inc., a company focused on therapies for neurological disorders, will present new data on its Phase 1 clinical trial evaluating rHIgM22, and five-year post-marketing safety data on AMPYRAĀ® (dalfampridine) Extended Release Tablets (10 mg) Ā at this year’sĀ 31st Congress of the European Committee for Treatment and Research in…
October 5, 2015 News by Patricia Silva, PhD Study Supports High Intensity Exercise to Improve Muscle Condition in MS Patients A new study recently published in the journal PLOS ONE revealed that high intensity exercise is safe and offers clinical benefits for patients with multiple sclerosis (MS). The study is entitled āHigh Intensity Exercise in Multiple Sclerosis: Effects on Muscle Contractile Characteristics and Exercise…
October 5, 2015 News by Charles Moore Multiple Sclerosis News Today To Provide Live, On-Site Coverage Of 31st Annual #ECTRIMS2015 Congress The 31st meeting of the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (#ECTRIMS2015) is being held this week from October 7 to 10 inĀ Barcelona, Spain. The conference was last held in the Catalonian capital in 1992. Multiple Sclerosis News Today…
September 29, 2015 News by Patricia Silva, PhD Could Genentechās Ocrelizumab Become the First Effective Primary Progressive MS Therapy? Genentech, a leading biotechnology company and member of the Roche Group, recently announced promising results on a pivotal Phase III clinical trial (ORATORIO) assessing its investigational therapyĀ ocrelizumab as a treatmentĀ for patients with primary progressive multiple sclerosis (PPMS). Multiple sclerosis (MS) is a chronic, progressive neurodegenerative disorder that results from…
September 24, 2015 News by Patricia Silva, PhD Medical Marijuana Use for Pain Relief in Medical Conditions like MS and AIDS Explored in New Nature Article Cannabis is a plant that can be usedĀ in a wide range ofĀ settings such as medical purposes, a source of fiber and oils, or as a recreational drug. Growing evidence has been reported on the clinical benefits of medical marijuana (herbal form) for treating chronic pain. Currently, several countries in the…
September 24, 2015 News by Patricia Inacio, PhD Brain-specific B Cells’ Reactivity Determines Glatiramer Acetate Therapy Success in MS Patients In a new study entitled āThe brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients,āĀ a team of scientists discovered that differences in response toĀ glatiramer acetate therapy among multiple sclerosis (MS) patients is potentially dependent on the presence of reactive brain-specific B…
September 23, 2015 News by Patricia Silva, PhD New Brain Cell Interaction Study Technique Could Impact MS Research A study led by researchers from the University ofĀ Buffalo recently reported the development of a new method to study brain cell interaction more precisely. The study, published in the journal Nature CommunicationsĀ andĀ entitled āSpatial mapping of juxtacrine axo-glial interactions identifies novel molecules in peripheral…
September 22, 2015 News by Patricia Silva, PhD Clinical Benefit of Relapsing-Remitting Multiple Sclerosis Therapies Highlighted in Review A review study recently published in the journal Cochrane Database of Systematic Review (CDSR) focused on the clinical benefit of different therapiesĀ available for relapsing-remitting multiple sclerosis (RRMS). The study is entitled āImmunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysisā and was led…
September 21, 2015 News by Patricia Silva, PhD Fingolimod (Gilenya) Found to Be an Effective Multiple Sclerosis Therapy for Up to Three Years of Treatment An encouraging newĀ analysis reveals that fingolimod isĀ an effective multiple sclerosis (MS) therapy forĀ a treatment period of up to three years. The results were presented at the Annual Meeting of the Consortium of MS Centers. MS is a chronic, progressive neurodegenerative disorder that is the result ofĀ anĀ attack onĀ the central nervous system…
September 18, 2015 News by Patricia Silva, PhD MS Views and News Reaches Two Locations For the First Time in October Non-profit,Ā MS News and Views (MSVN), which works nationally to increase education and knowledge about multiple sclerosis (MS), has announced the organization of two events during the month of October. For the first time, the organization will host two events with the exact same structure and theme,…